ME Therapeutics Holdings Inc.
METX
CNSX
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Net Income | -950.70K | -917.80K | -950.00K | -1.01M | -5.11M |
| Total Depreciation and Amortization | 21.90K | 7.60K | 0.00 | 0.00 | 0.00 |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 478.10K | 470.20K | 512.50K | 590.00K | 4.71M |
| Change in Net Operating Assets | -14.50K | 45.70K | -45.50K | -28.50K | -47.50K |
| Cash from Operations | -465.10K | -394.20K | -482.90K | -448.90K | -452.20K |
| Capital Expenditure | -114.00K | -6.40K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 0.00 | 558.20K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.90K | -7.90K | -- | -- | -- |
| Cash from Investing | -121.90K | -14.30K | -- | 0.00 | 558.20K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -21.70K | -45.40K | -40.00K | -40.00K | -40.00K |
| Issuance of Common Stock | 1.50M | 1.56M | 1.56M | 1.67M | 1.22M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7.50K | -7.50K | -7.50K | -- | -- |
| Cash from Financing | 1.04M | 1.11M | 1.12M | 1.21M | 879.40K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 455.90K | 704.90K | 634.50K | 760.70K | 985.50K |